Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GCK | P35557 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.36 |
| ▸ | MTOR | P42345 | 10/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22252667 | 0.78 | GRM5 (0.42) | GRM5KDM4CMEN1KMT2AGCK | |
| SCHEMBL21058120 | 0.78 | GRM5 (0.42) | GRM5KDM4CMEN1KMT2AGCK | |
| SCHEMBL9763296 | 0.78 | GRM5 (0.42) | GRM5KDM4CMEN1KMT2AGCK | |
| SCHEMBL5990774 | 0.77 | GRM5 (0.44) | GRM5KDM4CMEN1KMT2AGCK | |
| SCHEMBL31558454 | 0.75 | GRM5 (0.44) | GRM5KDM4CMEN1KMT2AGCK | |
| SCHEMBL23729876 | 0.74 | GRM5 (0.43) | GRM5KDM4CMEN1KMT2AGCK | |
| SCHEMBL23704078 | 0.74 | GRM5 (0.43) | GRM5KDM4CMEN1KMT2AGCK | |
| SCHEMBL31607849 | 0.73 | KDM4C (0.53) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL26641352 | 0.73 | KDM4C (0.53) | KDM4CMEN1KMT2AL3MBTL1NPC1 | |
| SCHEMBL31419836 | 0.73 | HTR2A (0.45) | GRM5KDM4CMEN1KMT2AGCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903097-B2 | Heterocycle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY (US) | 2005-06-07 | — | — | US | disclosed |
| US-20040142928-A1 | Heterocycle carboxamides as antiviral agents | BUNDY GORDON L (US) | 2004-07-22 | — | — | US | disclosed |
| US-20030207880-A1 | Heterocycle carboxamides as antiviral agents | BUNDY GORDON L (US) | 2003-11-06 | — | — | US | disclosed |
| US-6559145-B2 | Herpes virus | PHARMACIA & UPJOHN COMPANY | 2003-05-06 | — | — | US | disclosed |
| EP-1301493-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20020025960-A1 | Heterocycle carboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-02-28 | — | — | US | disclosed |
| WO-2002004444-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142928-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | GRM5 2975/4885KDM4C 355/4885MEN1 2250/4885 |
| US-20020025960-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | GRM5 2975/4885KDM4C 355/4885MEN1 2250/4885 |
| US-20030207880-A1 | Heterocycle carboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, HDAC1 | GRM5 2975/4885KDM4C 355/4885MEN1 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.